

August 20, 1963

Dr. J. Arthur Seaholm
A. H. Robins Company, Inc.
1407 Cummings Drive
Richmond 20, Virginia

Dear Dr. Seaholm:

In June, the Pharmacology Committee of the Missouri Institute of Psychiatry approved a pilot study of butaperazine dimaleate and the statement of investigators were filed with your office by Dr. Turan Itil. The design has not been changed and the study is in progress. I have, therefore, suggested that a new statement is not necessary.

As you are aware, the detailed study of a new drug, beyond minimal clinical observations, entails extensive record keeping and examinations of a specialized nature. At the present time, we can provide only the minimum clinical information. In the event that you have some interest in more detailed investigations, I would suggest that you visit and discuss these with us.

Sincerely yours,

Max Fink, M. D.
Director

MF:aw